Physician profile
Mark S Obrien
NPI 1235188525
$4,596.95
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,556 · 2020: $2,015 · 2021: $25.71.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,023.13 | 2019-2020 | |
| Amgen INC. | $660.00 | 2019-2020 | |
| Pfizer INC. | $493.20 | 2019-2020 | |
| Amarin Pharma, INC. | $419.35 | 2019-2020 | |
| Novo Nordisk INC | $407.84 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $287.55 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $277.31 | 2019-2020 | |
| Astellas Pharma US INC | $216.42 | 2019-2020 | |
| Lilly USA, LLC | $132.10 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $96.45 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $91.70 | 2019-2020 | |
| Glaxosmithkline, LLC. | $89.35 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $59.93 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $58.52 | 2019-2020 | |
| Mannkind Corporation | $47.35 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $37.84 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $36.01 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.62 | 2019 | |
| Eisai INC. | $22.32 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.42 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.25 | 2019 | |
| Abbvie INC. | $15.84 | 2019 | |
| Adlon Therapeutics L.P. | $14.57 | 2020 | |
| Mylan Specialty L.P. | $14.48 | 2019 | |
| Collegium Pharmaceutical, INC. | $13.11 | 2021 | |
| Sanofi Pasteur INC. | $13.05 | 2019 | |
| Esperion Therapeutics, INC. | $12.24 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.